| Animal Background: | Challenge Route: | Challenge Dose: | Mean Time to Death: |
|---|---|---|---|
| <p>BALB/C, CD-1</p> | <p>Intraperitoneal (IP), Intravenous (IV)</p> | <p>Strain Dependent</p> | <p>Strain and Route Dependent</p> |
| Standard Readouts: | Other Readouts: | ||
| <p>Weights, health and survival</p> | <p><a href="https://ibtbioservices.com/services/bacterial-assays/">Bacterial Assays (MIC)</a>, <a href="https://ibtbioservices.com/services/elisa/">ELISA</a>, <a href="https://ibtbioservices.com/services/luminex/">Luminex</a>, <a href="https://ibtbioservices.com/services/flow-cytometry/">Flow cytometry</a>, <a href="#">Bacterial load in organs</a></p> |
Description: Female BALB/c (n=75) mice were challenged with varying doses of USA300 NRS384 via the intravenous (IV) route.
Description: Female BALB/c (n=190) mice were challenged with varying doses of USA300 NRS384 via the intraperitoneal (IP) route.
Description: Female BALB/c (n=30) mice were challenged with 1x LD90 of USA300 NRS384 via the intraperitoneal (IP) route. All animals were challenged on day 0 and received treatment via the IP route twice daily for five days.
For Product Information,
Orders & Technical Support
products@integratedbiotherapeutics.com
For Services
services@ibtbioservices.com
